Images List Premium Download Classic

Cancer Cells

Cancer Cells-related patent applications - as published by the U.S. Patent and Trademark Office (USPTO).


loading
T cells with increased immunosuppression resistance
October 18, 2018 - N°20180298338

This invention relates to the treatment of cancer in an individual by administration of a population of modified t cells that express a recombinant camp phosphodiesterase (pde) or a fragment thereof and an antigen receptor which binds specifically to cancer cells in the individual. Populations of modified t cells and methods of producing populations of modified t cells are provided, ...
Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting
October 18, 2018 - N°20180298047

Disclosed are compounds for the selective labeling of cell-surface sugars in cancer cells. The compounds are activatable by triggers specific to cancer cells, and, when metabolized, label a cancer cell surface sugar with an azide chemical group.
Personalized medicine therapeutic minicircle
October 18, 2018 - N°20180296699

Bispecific antibodies (bsabs) have emerged as a class of promising anti-cancer and anti-infection biological drugs. They are capable of killing target cells, either cancer cells or microbe-infected cells, at levels of nanograms per milliliter serum in vivo, about 1e+5 folds more powerful than regular antibodies.
Cancer Cells Patent Pack
Download 290+ patent application PDFs
Cancer Cells Patent Applications
Download 290+ Cancer Cells-related PDFs
For professional research & prior art discovery
inventor
  • 290+ full patent PDF documents of Cancer Cells-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Markers of tumor cell response to anti-cancer therapy
October 11, 2018 - N°20180291468

Compositions and methods for determining circulating biomolecules before, during, and/or after treatment of a patient with an anti-cancer or anti-tumor drug (or putative drug) are described. Methods of treatments based on the compositions and methods described herein are also provided.
Spectral imaging for measurement of nuclear pathology features in cancer cells prepared for in situ ...
October 11, 2018 - N°20180291464

In general, the presently disclosed technology relates to identification of cancer subtypes. More specifically, the technology relates to methods for determining molecular drivers of cancer and/or progression using a multivariate image data and statistical analysis of in-situ molecular markers and morphological characteristics in the same cells of a biological sample suspected of b cancer.
Method for determining drug-sensitive human cell lines by analysis method in which measurement of activity ...
October 11, 2018 - N°20180291421

The present invention addresses the problem of providing a novel method for classifying cancer cells by an analysis method in which measurement of the activity of two types of protein kinase is used. Cancer cells are newly classified and drug sensitivity is predicted on the basis of the ratio of the activity of two types of protein kinase derived from ...
Cancer Cells Patent Pack
Download 290+ patent application PDFs
Cancer Cells Patent Applications
Download 290+ Cancer Cells-related PDFs
For professional research & prior art discovery
inventor
  • 290+ full patent PDF documents of Cancer Cells-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Recombinant bi-specific polypeptide for coordinately activating tumor-reactive t-cells and neutralizing immune suppression
October 11, 2018 - N°20180291114

The present invention relates generally to the field of generating fusion proteins to be used in cancer therapy, and more specifically, a bispecific t-cell engager recombinant polypeptide comprising an antibody, fragment thereof, or single chain variable fragment that binds to cd3 of a t-cell antigen receptor and an antibody, fragment thereof, or single chain variable fragment that binds to programmed ...
Antibodies, binding fragments, and methods of use
October 11, 2018 - N°20180291109

The present disclosure relates to anti-ssea4 antibodies and bindings fragments thereof comprising specific complementarity determining regions capable of high affinity binding to ssea4 molecules and ssea4-associated expressing tumor cells, such as breast cancer, pancreatic cancer, and renal cancer cells. The anti-ssea4 antibodies and binding fragments induce adcc or cdc effects in the targeted tumor cells and inhibit and/or ...
Composition having compound accelerating phosphorylation of ampk as effective component
October 11, 2018 - N°20180290979

Provided is a composition that can be used for an organ preservation solution or perfusate. Alternatively, provided is a composition for prolonging the survival of normal cells and/or a composition for inhibiting the survival of cancer cells.
Conjugates for treating diseases caused by psma expressing cells
October 11, 2018 - N°20180289826

The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by psma expressing cells, such as prostate cancer cells, using compounds capable of targeting psma expressing cells..
Methods for inducing apoptosis in cancer cells
October 11, 2018 - N°20180289693

Provided are methods for inducing apoptosis of cells using quinolinol compounds. Combinations of quinolinol compounds can be used in the methods.
Her3 vaccine vector compositions and methods of using the same
October 04, 2018 - N°20180282736

The present inventors provide her3 vaccine vector compositions and methods of using the same. More specifically, the present inventors demonstrate, in part, that a combination of her3 vaccine vectors with checkpoint inhibitors suppresses or eliminates cancer cells more effectively than either alone..
Peptide-based inhibitors of mll/set1 family core complexes
October 04, 2018 - N°20180282373

Provided are peptides, compositions comprising the peptides, and methods of using the peptide compositions for inhibition of growth of cancer cells. The peptides comprise a sequence of arx1x2x3x4, and inhibit or disrupt the formation of mll1 and set1 complexes..
Cancer Cells Patent Pack
Download 290+ patent application PDFs
Cancer Cells Patent Applications
Download 290+ Cancer Cells-related PDFs
For professional research & prior art discovery
inventor
  • 290+ full patent PDF documents of Cancer Cells-related inventions.
  • Exact USPTO filing data with full-text, images, drawings & claims.
  • Index pages: Table View and Image-Grid View layouts. All images in each PDF.
Activatable two-component photosensitizers
October 04, 2018 - N°20180280510

Provided herein is a two-component photosensitizer, which demonstrated robust and selective killing effects for transfected hek cells and affibody targeted a431 cancer cells when exposed to near infrared light excitation. Free mg2i is a pure and stable fluorogen; it is easy to synthesize and modify, and has no toxicity to cells.
Retinoid compositions and methods of increasing immune cell-mediated killing of idh mutant cancer cells
October 04, 2018 - N°20180280335

Provided herein are methods of treating an idh mutant cancer in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising an all-trans retinoic acid (atra). In some embodiments, the methods increase an nk-cell-mediated immune response and/or a t cell-mediated immune response to the cancer.
Cell yield for synthetic tissue controls and synthetic tissue microarray controls
Slmp, Llc
September 27, 2018 - N°20180275027

The disclosed embodiments include methods to improve yield of cultured cells of stc and stmc for use in determining presence of cancer, and methods to detect presence of cancer. In one embodiment, the method includes solidifying a fluidly gel to form a solid cell holder.
Antigen-binding constructs targeting her2
Zymeworks Inc.
September 27, 2018 - N°20180273635

Described herein are high affinity antigen binding constructs, e.g., antibodies, directed to the ecd2 domain of her2. The antigen-binding constructs comprise at least one antigen-binding polypeptide construct that binds to ecd2 of her2 (her2 ecd2) with increased affinity compared to a wild-type 2c4 antibody.
Her2 peptide regents and methods
The Regents Of The University Of Michigan
September 27, 2018 - N°20180273584

The present disclosure is directed to her2-specific peptide reagents, methods for detecting pre-cancer (dysplasia), early cancer and/or cancer using the peptide reagents, and methods for targeting pre-cancerous (dysplastic) cells, and/or cancer cells using the peptide reagents.. .
Platinum(ii) complexes with selone ligands and method of use
King Saud University
September 27, 2018 - N°20180273566

Platinum(ii) complexes with various selones (l) having the general formula ptl2cl2 are disclosed. The platinum(ii) complexes of the invention inhibit growth of cancer cells in vitro and are useful for treatment of proliferative disorders such as cancers and/or tumors..
Composition containing a gold (i) complex and cancer cells
King Saud University
September 27, 2018 - N°20180273558

Gold(i) complex with mixed ligands as an anticancer agent. The gold(i) ion is coordinated to a dithiocarbamate ligand and a phosphorus-containing ligand (e.g.
Small molecule inhibitors of lactate dehydrogenase and methods of use thereof
The United States Of America As Represented By The Secretary, Department Of He
September 27, 2018 - N°20180273488

Provided is a compound of formula (i) [formula (i) should be inserted here], in which ar1, r1, u, v, w, x, and p are as described herein. Also provided are methods of using a compound of formula (i), including a method of treating cancer, a method of treating a patient with cancer cells resistant to an anti-cancer agent, and a ...
Loading